{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T06:16:22Z","timestamp":1792649782302,"version":"4.5.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,12,21]]},"DOI":"10.7759\/cureus.99753","type":"journal-article","created":{"date-parts":[[2025,12,21]],"date-time":"2025-12-21T09:27:06Z","timestamp":1766309226000},"source":"Crossref","is-referenced-by-count":0,"title":["An Experimental Study to Evaluate the Role of Buprenorphine, Morphine, and Naltrexone in Animal Models of Depression"],"prefix":"10.7759","author":[{"given":"Nichwa Leuwenhoek","family":"Suja Nongtdu,","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veena","family":"Verma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31948-2","article-title":"Depression","volume":"392","author":"Malhi GS","year":"2018","unstructured":"Malhi GS, Mann JJ. Depression. Lancet. 2018, 392:2299-312. 10.1016\/S0140-6736(18)31948-2","journal-title":"Lancet"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S29716","article-title":"Treatment-resistant depression: therapeutic trends, challenges, and future directions","volume":"6","author":"Al-Harbi KS","year":"2012","unstructured":"Al-Harbi KS. Treatment-resistant depression: therapeutic trends, challenges, and future directions. Patient Prefer Adherence. 2012, 6:369-88. 10.2147\/PPA.S29716","journal-title":"Patient Prefer Adherence"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3390\/ph15101203","article-title":"Monoamine neurotransmitters control basic emotions and affect major depressive disorders","volume":"15","author":"Jiang Y","year":"2022","unstructured":"Jiang Y, Zou D, Li Y, et al.. Monoamine neurotransmitters control basic emotions and affect major depressive disorders. Pharmaceuticals (Basel). 2022, 15:1203. 10.3390\/ph15101203","journal-title":"Pharmaceuticals (Basel)"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.dscb.2025.100270","article-title":"Current drug targets for the treatment of depression","volume":"19","author":"Pathak g","year":"2025","unstructured":"Pathak g, Nigade A, Anitha K, Bhatt S. Current drug targets for the treatment of depression. Brain Disord. 2025, 19:100270. 10.1016\/j.dscb.2025.100270","journal-title":"Brain Disord"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.neubiorev.2022.104800","article-title":"The opioid system in depression","volume":"140","author":"Jelen LA","year":"2022","unstructured":"Jelen LA, Stone JM, Young AH, Mehta MA. The opioid system in depression. Neurosci Biobehav Rev. 2022, 140:104800. 10.1016\/j.neubiorev.2022.104800","journal-title":"Neurosci Biobehav Rev"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.tins.2012.11.002","article-title":"Opioid receptors: distinct roles in mood disorders","volume":"36","author":"Lutz PE","year":"2013","unstructured":"Lutz PE, Kieffer BL. Opioid receptors: distinct roles in mood disorders. Trends Neurosci. 2013, 36:195-206. 10.1016\/j.tins.2012.11.002","journal-title":"Trends Neurosci"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.23-13-05674.2003","article-title":"Kappa opioid receptor antagonism and prodynorphin gene disruption block stress-induced behavioral responses","volume":"23","author":"McLaughlin JP","year":"2003","unstructured":"McLaughlin JP, Marton-Popovici M, Chavkin C. Kappa opioid receptor antagonism and prodynorphin gene disruption block stress-induced behavioral responses. J Neurosci. 2003, 23:5674-83. 10.1523\/JNEUROSCI.23-13-05674.2003","journal-title":"J Neurosci"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.102.046433","article-title":"Antidepressant-like effects of kappa-opioid receptor antagonists in the forced swim test in rats","volume":"305","author":"Mague SD","year":"2003","unstructured":"Mague SD, Pliakas AM, Todtenkopf MS, et al.. Antidepressant-like effects of kappa-opioid receptor antagonists in the forced swim test in rats. J Pharmacol Exp Ther. 2003, 305:323-30. 10.1124\/jpet.102.046433","journal-title":"J Pharmacol Exp Ther"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.2174\/1570159043359477","article-title":"Buprenorphine: a unique drug with complex pharmacology","volume":"2","author":"Lutfy K","year":"2004","unstructured":"Lutfy K, Cowan A. Buprenorphine: a unique drug with complex pharmacology. Curr Neuropharmacol. 2004, 2:395-402. 10.2174\/1570159043359477","journal-title":"Curr Neuropharmacol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/0006-3223(90)90619-d","article-title":"Buprenorphine responders","volume":"28","author":"Mongan L","year":"1990","unstructured":"Mongan L, Callaway E. Buprenorphine responders. Biol Psychiatry. 1990, 28:1078-80. 10.1016\/0006-3223(90)90619-d","journal-title":"Biol Psychiatry"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-014-3723-y","article-title":"Effects of buprenorphine on behavioral tests for antidepressant and anxiolytic drugs in mice","volume":"232","author":"Falcon E","year":"2015","unstructured":"Falcon E, Maier K, Robinson SA, Hill-Smith TE, Lucki I. Effects of buprenorphine on behavioral tests for antidepressant and anxiolytic drugs in mice. Psychopharmacology (Berl). 2015, 232:907-15. 10.1007\/s00213-014-3723-y","journal-title":"Psychopharmacology (Berl)"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/0740-5472(90)90035-o","article-title":"Depressive symptoms during buprenorphine treatment of opioid abusers","volume":"7","author":"Kosten TR","year":"1990","unstructured":"Kosten TR, Morgan C, Kosten TA. Depressive symptoms during buprenorphine treatment of opioid abusers. J Subst Abuse Treat. 1990, 7:51-4. 10.1016\/0740-5472(90)90035-o","journal-title":"J Subst Abuse Treat"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2015.15040535","article-title":"Ultra-low-dose buprenorphine as a time-limited treatment for severe suicidal ideation: a randomized controlled trial","volume":"173","author":"Yovell Y","year":"2016","unstructured":"Yovell Y, Bar G, Mashiah M, et al.. Ultra-low-dose buprenorphine as a time-limited treatment for severe suicidal ideation: a randomized controlled trial. Am J Psychiatry. 2016, 173:491-8. 10.1176\/appi.ajp.2015.15040535","journal-title":"Am J Psychiatry"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1177\/0269881115586937","article-title":"Combined administration of buprenorphine and naltrexone produces antidepressant-like effects in mice","volume":"29","author":"Almatroudi A","year":"2015","unstructured":"Almatroudi A, Husbands SM, Bailey CP, Bailey SJ. Combined administration of buprenorphine and naltrexone produces antidepressant-like effects in mice. J Psychopharmacol. 2015, 29:812-21. 10.1177\/0269881115586937","journal-title":"J Psychopharmacol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.4103\/0976-500X.119726","article-title":"How to calculate sample size in animal studies?","volume":"4","author":"Charan J","year":"2013","unstructured":"Charan J, Kantharia ND. How to calculate sample size in animal studies?. J Pharmacol Pharmacother. 2013, 4:303-6. 10.4103\/0976-500X.119726","journal-title":"J Pharmacol Pharmacother"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0004326","article-title":"Chronic mild stress (CMS) in mice: of anhedonia, 'anomalous anxiolysis' and activity","volume":"4","author":"Schweizer MC","year":"2009","unstructured":"Schweizer MC, Henniger MS, Sillaber I. Chronic mild stress (CMS) in mice: of anhedonia, 'anomalous anxiolysis' and activity. PLoS One. 2009, 4:e4326. 10.1371\/journal.pone.0004326","journal-title":"PLoS One"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.21769\/BioProtoc.1958","article-title":"Sucrose preference test to measure anhedonic behaviour in mice","volume":"6","author":"Serchov T","year":"2016","unstructured":"Serchov T, Van Calker D, Biber K . Sucrose preference test to measure anhedonic behaviour in mice. Bio-protocol J. 2016, 6:e1958. 10.21769\/BioProtoc.1958","journal-title":"Bio-protocol J"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.3791\/52434","article-title":"Use of the open field maze to measure locomotor and anxiety-like behavior in mice","author":"Seibenhener ML","year":"2015","unstructured":"Seibenhener ML, Wooten MC. Use of the open field maze to measure locomotor and anxiety-like behavior in mice. J Vis Exp. 2015, e52434. 10.3791\/52434","journal-title":"J Vis Exp"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.3791\/3638","article-title":"The mouse forced swim test","author":"Can A","year":"2012","unstructured":"Can A, Dao DT, Arad M, Terrillion CE, Piantadosi SC, Gould TD. The mouse forced swim test. J Vis Exp. 2012, e3638. 10.3791\/3638","journal-title":"J Vis Exp"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.3791\/3769","article-title":"The tail suspension test","author":"Can A","year":"2012","unstructured":"Can A, Dao DT, Terrillion CE, Piantadosi SC, Bhat S, Gould TD. The tail suspension test. J Vis Exp. 2012, e3769. 10.3791\/3769","journal-title":"J Vis Exp"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1097\/ALN.0b013e318238fea0","article-title":"Buprenorphine metabolites, buprenorphine-3-glucuronide and norbuprenorphine-3-glucuronide, are biologically active","volume":"115","author":"Brown SM","year":"2011","unstructured":"Brown SM, Holtzman M, Kim T, Kharasch ED. Buprenorphine metabolites, buprenorphine-3-glucuronide and norbuprenorphine-3-glucuronide, are biologically active. Anesthesiology. 2011, 115:1251-60. 10.1097\/ALN.0b013e318238fea0","journal-title":"Anesthesiology"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1017\/S1461145711001842","article-title":"Active behaviours produced by antidepressants and opioids in the mouse tail suspension test","volume":"16","author":"Berrocoso E","year":"2013","unstructured":"Berrocoso E, Ikeda K, Sora I, Uhl GR, S\u00e1nchez-Bl\u00e1zquez P, Mico JA. Active behaviours produced by antidepressants and opioids in the mouse tail suspension test. Int J Neuropsychopharmacol. 2013, 16:151-62. 10.1017\/S1461145711001842","journal-title":"Int J Neuropsychopharmacol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.pbb.2012.10.013","article-title":"Morphine prevents the development of stress-enhanced fear learning","volume":"103","author":"Szczytkowski-Thomson JL","year":"2013","unstructured":"Szczytkowski-Thomson JL, Lebonville CL, Lysle DT. Morphine prevents the development of stress-enhanced fear learning. Pharmacol Biochem Behav. 2013, 103:672-7. 10.1016\/j.pbb.2012.10.013","journal-title":"Pharmacol Biochem Behav"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1007\/BF00433065","article-title":"Biphasic effects of a potent enkephalin analogue (D-Met2,Pro5)-enkephalinamide and morphine on locomotor activity in mice","volume":"71","author":"Sz\u00e9kely JI","year":"1980","unstructured":"Sz\u00e9kely JI, Migl\u00e9cz E, R\u00f3nai AZ. Biphasic effects of a potent enkephalin analogue (D-Met2,Pro5)-enkephalinamide and morphine on locomotor activity in mice. Psychopharmacology (Berl). 1980, 71:299-301. 10.1007\/BF00433065","journal-title":"Psychopharmacology (Berl)"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1007\/s002130050922","article-title":"The effects of dopamine D2 and D3 antagonists on spontaneous motor activity and morphine-induced hyperactivity in male mice","volume":"143","author":"Manzanedo C","year":"1999","unstructured":"Manzanedo C, Aguilar MA, Mi\u00f1arro J. The effects of dopamine D2 and D3 antagonists on spontaneous motor activity and morphine-induced hyperactivity in male mice. Psychopharmacology (Berl). 1999, 143:82-8. 10.1007\/s002130050922","journal-title":"Psychopharmacology (Berl)"},{"key":"ref26","doi-asserted-by":"crossref","DOI":"10.1016\/S0022-3565(24)39003-2","article-title":"Dose- and time-dependent bimodal effects of kappa-opioid agonists on locomotor activity in mice","volume":"295","author":"Kuzmin A","year":"2000","unstructured":"Kuzmin A, Sandin J, Terenius L, Ogren SO. Dose- and time-dependent bimodal effects of kappa-opioid agonists on locomotor activity in mice. J Pharmacol Exp Ther. 2000, 295:1031-42.","journal-title":"J Pharmacol Exp Ther"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2021.642493","article-title":"The role of the kappa opioid system in comorbid pain and psychiatric disorders: function and implications","volume":"15","author":"Ji MJ","year":"2021","unstructured":"Ji MJ, Yang J, Gao ZQ, Zhang L, Liu C. The role of the kappa opioid system in comorbid pain and psychiatric disorders: function and implications. Front Neurosci. 2021, 15:642493. 10.3389\/fnins.2021.642493","journal-title":"Front Neurosci"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1038\/npp.2015.258","article-title":"Dynorphin, dysphoria, and dependence: the stress of addiction","volume":"41","author":"Chavkin C","year":"2016","unstructured":"Chavkin C, Koob GF. Dynorphin, dysphoria, and dependence: the stress of addiction. Neuropsychopharmacology. 2016, 41:373-4. 10.1038\/npp.2015.258","journal-title":"Neuropsychopharmacology"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2011.06.014","article-title":"Blockade of kappa opioid receptors attenuates the development of depressive-like behaviors induced by cocaine withdrawal in rats","volume":"62","author":"Chartoff E","year":"2012","unstructured":"Chartoff E, Sawyer A, Rachlin A, Potter D, Pliakas A, Carlezon WA. Blockade of kappa opioid receptors attenuates the development of depressive-like behaviors induced by cocaine withdrawal in rats. Neuropharmacology. 2012, 62:167-76. 10.1016\/j.neuropharm.2011.06.014","journal-title":"Neuropharmacology"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2024.07.030","article-title":"Preclinical and clinical efficacy of kappa opioid receptor antagonists for depression: a systematic review","volume":"362","author":"Wong S","year":"2024","unstructured":"Wong S, Le GH, Vasudeva S, et al.. Preclinical and clinical efficacy of kappa opioid receptor antagonists for depression: a systematic review. J Affect Disord. 2024, 362:816-27. 10.1016\/j.jad.2024.07.030","journal-title":"J Affect Disord"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/417404-an-experimental-study-to-evaluate-the-role-of-buprenorphine-morphine-and-naltrexone-in-animal-models-of-depression","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,21]],"date-time":"2025-12-21T09:27:07Z","timestamp":1766309227000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/417404-an-experimental-study-to-evaluate-the-role-of-buprenorphine-morphine-and-naltrexone-in-animal-models-of-depression"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,21]]},"references-count":30,"URL":"https:\/\/doi.org\/10.7759\/cureus.99753","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12,21]]}}}